Table 3 Results of the fixed-effect direct, Bucher indirect and NMA comparisons

WMD v placebo

Direct comparison

WMD v placebo

Direct comparison

OR v placebo

Direct comparison

DPP-4 v placebo

-0.56 (-0.70, -0.41)†

-0.56 (-0.70, -0.41)*

0.57 (0.09, 1.06)†

0.57 (0.09, 1.05)*

1.87 (0.82, 4.72)

1.8 (0.78, 4.17)

GLP-1 v placebo

-0.80 (-1.04, -0.56)†

-0.79 (-1.02, -0.55)*

-0.65 (-1.37, 0.07)

-0.65 (-1.37, 0.07)

10.89 (4.24, 38.28)†

10.05 (3.60, 28.06)*

SGLT2 v placebo

-0.69 (-0.86, -0.52)†

-0.69 (-0.86, -0.52)*

-1.54 (-2.16, -0.92)†

-1.54 (-2.16, -0.92)*

1.75 (0.67, 4.89)

1.71 (0.66, 4.48)

WMD head-to-head

Bucher indirect comparison

WMD head-to-head

Bucher indirect comparison

OR head-to-head

Bucher indirect comparison

GLP-1 v DPP-4

-0.24 (-0.52, 0.04)

-0.23 (-0.50, 0.04)

-1.23 (-2.09, -0.36)†

-1.22 (-2.09, -0.35)*

5.89 (1.56, 26.06)†

5.58 (1.49, 20.99)*

SGLT2 v DPP-4

-0.13 (-0.35, 0.09)

-0.13 (-0.35, 0.09)

-2.11 (-2.90, -1.33)†

-2.11(-2.90, -1.33)*

0.94 (0.25, 3.50)

0.95 (0.27, 3.37)

SGLT2 v GLP-1

0.11 (-0.18, 0.40)

0.10 (-0.19, 0.39)

-0.89 (-1.84, 0.07)

-0.89 (-1.84, 0.06)

0.16 (0.03, 0.65)†

0.17 (0.04, 0.69)*

WMD v baseline

WMD v baseline

Probability of hypoglycaemia

placebo

0.05 (-0.10, 0.20)

N/A

-0.48 (-0.78, -0.18)†

N/A

3.99% (2.30%, 6.85%)

N/A

DPP-4

-0.51 (-0.72, -0.30)†

N/A

0.09 (-0.47, 0.66)

N/A

7.23% (2.75%, 18.67%)

N/A

GLP-1

-0.75 (-1.03, -0.47)†

N/A

-1.13 (-1.91, -0.35)†

N/A

31.38% (13.00%, 64.10%)

N/A

SGLT2

-0.64 (-0.87, -0.42)†

N/A

-2.02 (-2.71, -1.33)†

N/A

6.81% (2.33%, 19.04%)

N/A

Model parameter results

DIC (WinBUGs)

-10.36

N/A

13.07

N/A

72.301

N/A

Average resdev

1.37

N/A

1.14

N/A

2.25

N/A